Last updated on May 2019

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13 in Healthy Infants (V114-031/PNEU-LINK)

Brief description of study

This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13 in healthy infants. This study will include both full-term infants (37 weeks gestational age) and premature infants (<37 weeks gestational age). Premature infants will be included in a Premature Infant Immunogenicity Substudy, which will assess immunogenicity and safety following administration of V114 or Prevnar 13.

Clinical Study Identifier: NCT03692871

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.